PRODUCT

MatrixCellect® 100 DBM Crunch

MatrixCellect® 100 DBM Crunch is processed using CellRight Technologies® proprietary demineralization process. It has been histologically proven post-sterilization to exhibit five elements of bone formation. MatrixCellect® 100 DBM Crunch does not contain any extrinsic carriers and is entirely derived from 100% allograft bone. MatrixCellect® 100 DBM Crunch is provided in a syringe.

MatrixCellect® 100 DBM Crunch is provided with a medical device Sterility Assurance Level (SAL) 10-6. The product should be stored at room temperature (15 ̊C – 30 ̊C), and has a shelf life of Two-Years from the date of packaging.

CellRight Technologies® employs strict quality assurance and quality control procedures to ensure patient safety. CellRight’s medical director, a licensed physician, performs an extensive medical review of the donor’s medical/social history to determine eligibility. Only donors whose screening, serologic, and microbiologic tests meet or exceed the current standards established by the Food and Drug Administration (FDA) and the American Association of Tissue Banks (AATB) are accepted for transplantation.

MatrixCellect® 100 DBM Crunch is indicated for homologous use for the treatment of surgically created or traumatic skeletal defects.